Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders' Equity

v3.19.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Balance at beginning of period at Dec. 31, 2017 $ 84,947 $ 4 $ 535,503 $ (44) $ (450,516)
Balance at beginning of period (in shares) at Dec. 31, 2017   44,408,796      
Issuance of common stock upon exercise of warrants, value 3,753   3,753    
Issuance of common stock upon exercise of warrants (Shares)   297,144      
Issuance of common stock upon exercise of stock options and incentive awards 3,276   3,276    
Issuance of common stock upon exercise of stock options and incentive awards (Shares)   667,656      
Stock-based compensation expense 1,796   1,796    
Issuance costs of common stock, net of issuance costs, value 135,520 $ 2 135,518    
Issuance costs of common stock, net of issuance costs (Shares)   13,340,000      
Net loss (17,005)       (17,005)
Net unrealized gain (loss) on marketable securities (88)     (88)  
Balance at end of period at Mar. 31, 2018 212,199 $ 6 679,846 (132) (467,521)
Balance at end of period (in shares) at Mar. 31, 2018   58,713,596      
Balance at beginning of period at Dec. 31, 2017 84,947 $ 4 535,503 (44) (450,516)
Balance at beginning of period (in shares) at Dec. 31, 2017   44,408,796      
Net loss (53,099)        
Net unrealized gain (loss) on marketable securities 13        
Balance at end of period at Sep. 30, 2018 188,131 $ 6 691,771 (31) (503,615)
Balance at end of period (in shares) at Sep. 30, 2018   59,439,130      
Balance at beginning of period at Mar. 31, 2018 212,199 $ 6 679,846 (132) (467,521)
Balance at beginning of period (in shares) at Mar. 31, 2018   58,713,596      
Issuance of common stock upon exercise of warrants, value 2,484   2,484    
Issuance of common stock upon exercise of warrants (Shares)   185,507      
Issuance of common stock upon exercise of stock options and incentive awards 245   245    
Issuance of common stock upon exercise of stock options and incentive awards (Shares)   60,833      
Stock-based compensation expense 1,751   1,751    
Net loss (17,531)       (17,531)
Net unrealized gain (loss) on marketable securities 65     65  
Balance at end of period at Jun. 30, 2018 199,213 $ 6 684,326 (67) (485,052)
Balance at end of period (in shares) at Jun. 30, 2018   58,959,936      
Issuance of common stock upon exercise of warrants, value 5,691   5,691    
Issuance of common stock upon exercise of warrants (Shares)   474,194      
Issuance of common stock upon exercise of stock options and incentive awards 26   26    
Issuance of common stock upon exercise of stock options and incentive awards (Shares)   5,000      
Stock-based compensation expense 1,728   1,728    
Net loss (18,563)       (18,563)
Net unrealized gain (loss) on marketable securities 36     36  
Balance at end of period at Sep. 30, 2018 188,131 $ 6 691,771 (31) (503,615)
Balance at end of period (in shares) at Sep. 30, 2018   59,439,130      
Balance at beginning of period at Dec. 31, 2018 170,418 $ 6 693,534 (58) (523,064)
Balance at beginning of period (in shares) at Dec. 31, 2018   59,456,493      
Issuance of common stock upon exercise of stock options and incentive awards 97   97    
Issuance of common stock upon exercise of stock options and incentive awards (Shares)   37,550      
Stock-based compensation expense 2,342   2,342    
Issuance costs of common stock, net of issuance costs, value 107,746 $ 1 107,745    
Issuance costs of common stock, net of issuance costs (Shares)   9,200,000      
Net loss (23,075)       (23,075)
Net unrealized gain (loss) on marketable securities 103     103  
Balance at end of period at Mar. 31, 2019 257,631 $ 7 803,718 45 (546,139)
Balance at end of period (in shares) at Mar. 31, 2019   68,694,043      
Balance at beginning of period at Dec. 31, 2018 170,418 $ 6 693,534 (58) (523,064)
Balance at beginning of period (in shares) at Dec. 31, 2018   59,456,493      
Net loss (73,395)        
Net unrealized gain (loss) on marketable securities 235        
Balance at end of period at Sep. 30, 2019 212,591 $ 7 808,866 177 (596,459)
Balance at end of period (in shares) at Sep. 30, 2019   68,701,043      
Balance at beginning of period at Mar. 31, 2019 257,631 $ 7 803,718 45 (546,139)
Balance at beginning of period (in shares) at Mar. 31, 2019   68,694,043      
Issuance of common stock upon exercise of stock options and incentive awards 7   7    
Issuance of common stock upon exercise of stock options and incentive awards (Shares)   7,000      
Stock-based compensation expense 2,276   2,276    
Net loss (24,038)       (24,038)
Net unrealized gain (loss) on marketable securities 183     183  
Balance at end of period at Jun. 30, 2019 236,059 $ 7 806,001 228 (570,177)
Balance at end of period (in shares) at Jun. 30, 2019   68,701,043      
Stock-based compensation expense 2,865   2,865    
Net loss (26,282)       (26,282)
Net unrealized gain (loss) on marketable securities (51)     (51)  
Balance at end of period at Sep. 30, 2019 $ 212,591 $ 7 $ 808,866 $ 177 $ (596,459)
Balance at end of period (in shares) at Sep. 30, 2019   68,701,043